2023 Annual Business Report

Our capital strategy

Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.

Our capital strategy

Our Financials & Outlook

  • In 2022, Valneva raised approximately €102.9 million of gross proceeds from an upsized global offering in a challenging economic environment.
  • Pfizer made a €90.5 ($95) million equity investment in Valneva, representing 8.1% of Valneva’s share capital at a price of €9.49 per share, to further support the strategic Lyme partnership between the two companies.
  • Valneva drew down a total of €40 million of additional funds from its Deerfield & OrbiMed loan agreement.